In addition, the WHO in 2016 included IDH mutations and 1p/19q combined deletions into the classification and diagnosis of gliomas (Louis 2016), which indicates that molecular characteristics play an increasingly important role in the diagnosis, treatment, and prognosis evaluation of gliomas. This evidence concerns the gene IDH1 and central nervous system cancer.